Trial · NCT01451996
The Efficacy of Claritin in Healthy Subjects
NCT01451996, Phase 4, Completed, University of Chicago; results first posted 2018-03-13
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Efficacy of Claritin in Healthy Subjects. Trials, record NCT01451996. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01451996
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Efficacy of Claritin in Healthy Subjects
- NCT number
- NCT01451996
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 340 participants, actual
- Lead sponsor
- University of Chicago
- Conditions
- Healthy
- Interventions
- Claritin
- First posted
- 2011-10-14
- Last updated
- 2018-03-13
- Results first posted
- 2018-03-13
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Wheal Reaction Area From Baseline --- 2 Hour | baseline and 2 hours post administration of Claritin. | A research technician, blinded to the subject's condition, measured the extent of the skin inflammation at baseline and 2 hours post Claritin administration by tracing the wheal reaction after the histamine challenge (i.e. the slightly reddened, elevated area at the site of the challenge, a well-established measure of histamine response). The percentage change in the wheal reaction was calculated as the change (decrease) in the size relative to baseline, multiplied by 100. Wheal area was measured in mm\^2. |
| Secondary | Change in Wheal Reaction Area From Baseline --- 1 Hour | baseline and 1 hours post administration of Claritin | A research technician, blinded to the subject's condition, measured the extent of the skin inflammation at baseline and 1 hour post Claritin administration by tracing the wheal reaction after the histamine challenge (i.e. the slightly reddened, elevated area at the site of the challenge, a well-established measure of histamine response). The percentage change in the wheal reaction was calculated as the change (decrease) in the size relative to baseline, multiplied by 100. Wheal area was measured in mm\^2. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Wheal Reaction Area From Baseline --- 2 Hour | baseline and 2 hours post administration of Claritin. | Percent change | MEAN | |
| SECONDARY | Change in Wheal Reaction Area From Baseline --- 1 Hour | baseline and 1 hours post administration of Claritin | Percent change | MEAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Wheal Reaction Area From Baseline --- 2 Hour | Claritin Ads, Allergy+ | 27.5 | Standard Error 2.5 | Percent change | |
| Change in Wheal Reaction Area From Baseline --- 2 Hour | Zyrtec Ads, Allergy+ | 29.0 | Standard Error 2.5 | Percent change | |
| Change in Wheal Reaction Area From Baseline --- 2 Hour | Claritin Ads, Allergy- | 30.97 | Standard Error 2.4 | Percent change | |
| Change in Wheal Reaction Area From Baseline --- 2 Hour | Zyrtec Ads, Allergy- | 25.0 | Standard Error 2.5 | Percent change | |
| Change in Wheal Reaction Area From Baseline --- 1 Hour | Claritin Ads, Allergy+ | 10.8 | Standard Error 2 | Percent change | |
| Change in Wheal Reaction Area From Baseline --- 1 Hour | Zyrtec Ads, Allergy+ | 17.5 | Standard Error 2.5 | Percent change | |
| Change in Wheal Reaction Area From Baseline --- 1 Hour | Claritin Ads, Allergy- | 14.18 | Standard Error 3 | Percent change | |
| Change in Wheal Reaction Area From Baseline --- 1 Hour | Zyrtec Ads, Allergy- | 10.83 | Standard Error 3 | Percent change |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Claritin Ads, Allergy+ | 83 | |
| Overall Study | STARTED | Zyrtec Ads, Allergy+ | 87 | |
| Overall Study | STARTED | Claritin Ads, Allergy- | 85 | |
| Overall Study | STARTED | Zyrtec Ads, Allergy- | 85 | |
| Overall Study | COMPLETED | Claritin Ads, Allergy+ | 83 | |
| Overall Study | COMPLETED | Zyrtec Ads, Allergy+ | 87 | |
| Overall Study | COMPLETED | Claritin Ads, Allergy- | 85 | |
| Overall Study | COMPLETED | Zyrtec Ads, Allergy- | 85 | |
| Overall Study | NOT COMPLETED | Claritin Ads, Allergy+ | 0 | |
| Overall Study | NOT COMPLETED | Zyrtec Ads, Allergy+ | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Claritin Ads, Allergy+ | ||
| Total, all-cause mortality | Zyrtec Ads, Allergy+ | ||
| Total, all-cause mortality | Claritin Ads, Allergy- | ||
| Total, all-cause mortality | Zyrtec Ads, Allergy- | ||
| Total, other adverse events | Claritin Ads, Allergy+ | 0 | 83 |
| Total, other adverse events | Zyrtec Ads, Allergy+ | 0 | 87 |
| Total, other adverse events | Claritin Ads, Allergy- | 0 | 85 |
| Total, other adverse events | Zyrtec Ads, Allergy- | 0 | 85 |
| Total, serious adverse events | Claritin Ads, Allergy+ | 0 | 83 |
| Total, serious adverse events | Zyrtec Ads, Allergy+ | 0 | 87 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01451996
GET https://conductscience.org/api/trials/v1/NCT01451996/registered